Limited functional and metabolic improvements in hypertrophic and healthy rat heart overexpressing the skeletal muscle isoform of SERCA1 by adenoviral gene transfer in vivo

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 295, Issue 6, 2008, Pages

  O'Donnell, J Michael ^a   Fields, Aaron ^a   Xu, Xianyao ^a   Chowdhury, Shamim A K ^b   Geenen, David L ^b   Bi, Jian ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Fatty acid oxidation; Glucose oxidation; Myocardial energy potential; Phosphocreatine to ATP ratio; Sarco(endo)plasmic reticulum Ca2+ ATPase

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADENOVIRUS VECTOR; CREATINE PHOSPHATE; ISOPRENALINE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE;

ADRENERGIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; ECHOCARDIOGRAPHY; GENE TRANSFER; HEART HYPERTROPHY; HEART MUSCLE METABOLISM; IN VIVO STUDY; MALE; NONHUMAN; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ADENOSINE TRIPHOSPHATE; ADENOVIRIDAE; ADRENERGIC BETA-AGONISTS; ANIMALS; CARDIOMEGALY; CARRIER PROTEINS; CITRIC ACID CYCLE; DISEASE MODELS, ANIMAL; ENERGY METABOLISM; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEMODYNAMICS; ISOPROTERENOL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MITOCHONDRIA, HEART; MUSCLE, SKELETAL; MYOCARDIAL CONTRACTION; MYOCARDIUM; OXIDATION-REDUCTION; PALMITIC ACID; PHOSPHOCREATINE; RATS; RATS, SPRAGUE-DAWLEY; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; TIME FACTORS;

EID: 57349157738     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01023.2008     Document Type: Article

References (66)

1. Arai M, Suzuki Tadashi Nagai R. Sarcoplasmic reticulum genes are up regulated in mild cardiac hypertrophy but down regulated in severe cardiac hypertrophy induced by pressure overload. J Mol Cell Cardiol 28: 1583-1590, 1996.
2. Belke DD, Swanson E, Suarez J, Scott BT, Stenbit AE, Dillmann WH. Increased expression of SERCA in the hearts of transgenic mice results in increased oxidation of glucose. Am J Physiol Heart Circ Physiol 292: H1755-H1763, 2007.
3. Beuckelmann DJ, Nabauer M, Erdmann E. Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation 85: 1046-1055, 1992.
4. Bristow MR, Minobe WA, Reynolds MV, Port JD, Rasmussen R, Ray PE, et al. Reduced b1 receptor messenger RNA abundance in the failing human heart. J Clin Invest 92: 2737-2745, 1993.
5. 2+ transients of embryonic chicken and neonatal rat cardiac myocytes. J Physiol 528: 53-63, 2000.
6. Chandler MP, Kerner J, Huang H, Vazquez E, Reszko A, Martini WZ. Moderate severity heart failure does not involve a downreguation of myocardial fatty acid oxidation. Am J Physiol Heart Circ Physiol 287: H1538-H1543, 2004.
7. Del Monte F, Harding S, Schmidt U, Matsui T, Kang Z, William GD, Gwathmey JK, Rosenzweig A, Hajjar RJ. Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation 100: 2308-2311, 1999.
8. 2+-ATPase in a rat model of heart failure. Circulation 104: 1424-1429, 2001.
9. Del Monte F, Butler K, Boecker W, Gwathmey JK, Hajjar RJ. Novel technique of aortic banding followed by gene transfer during hypertrophy and heart failure. Physiol Genomics 9: 49-56, 2002.
10. Fragasso G, Perseghin G, DeCobelli F, Esposito A, Palloshi A, Lattuada G, Scifo P, Calori G, DelMaschio A, Margonato A. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J 27: 942-948, 2006.
11. Fragasso G. Inhibition of free fatty acids metabolism as a therapeutic target in patients with heart failure. Int J Clin Pract 61: 603-610, 2007.
12. Gwathmey JK, Copelas L, MacKinnon R, Schoen FJ, Feldman MD, Grossman W, Morgan JP. Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res 61: 701-76, 1987.
13. 2+ in cells and tissues. J Bioenerg Biomembr 23: 823-854, 1991.
14. 2+ ATPase gene in the heart of transgenic mice accelerates calcium transients and cardiac relaxation. J Clin Invest 100: 380-389, 1997.
15. Hinken AC, Solaro RJ. A dominant role of cardiac molecular motors in the intrinsic regulation of ventricular ejection and relaxation. Physiology (Bethesda) 22: 73-80, 2007.
16. Hiranandani N, Raman S, Kalyanasundaram A, Periasamy M, Janssen PML. Frequency-dependent contractile strength in mice over- and under-expressing the sarco(endo)plasmic reticulum calcium-ATPase. Am J Physiol Regul Integr Comp Physiol 293: R30-R36, 2007.
17. Huke S, Prasad V, Nieman ML, Nattamai KJ, Grupp IL, Lorenz JN, Periasamy M. Altered dose response to β-agonists in SERCA1-expressing hearts ex vivo and in vivo. Am J Physiol Heart Circ Physiol 283: H958-H966, 2002.
18. Inesi G, Lewis D, Sumbilla C, Nandi A, Strock C, Huff KW, Rogers TB, Johns DC, Kessler PD, Ordahl CP. Cell-specific promoter in adenovirus vector for transgenic expression of SERCA 1 ATPase in cardiac myocytes. Am J Physiol Cell Physiol 274: C655-C663, 1998.
19. Inesi G, Cavagna M, O'Donnell JM, Sumbilla C, Zhong L, Ma H, Klein MG. Adenovirus-mediated gene transfer of SERCA isoforms. In: Molecular Approaches to the Therapy of Heart Failure, edited by Hasenfuss G and Marban E. Darmstadt, Germany: Springer-Steinkopff, 2000.
20. Izumo S, Shioi T. Cardiac transgenic and gene-targeted mice as models of cardiac hypertrophy and failure: a problem of (new) riches. J Card Fail 4: 263-270, 1998.
21. Janssen PML, Periasamy M. Determinants of frequency-dependent contraction and relaxation of mammalian myocardium. J Mol Cell Cardiol 43: 523-531, 2007.
22. Janssen PM, Stull LB, Marban E. Myofilament properties comprise the rate-limiting step for cardiac relaxation at body temperature in the rat. Am J Physiol Heart Circ Physiol 282: H499-H507, 2002.
23. Kawase Y, Ly GQ, Prunier F, Lebeche D, Shi Y, Jin H, Hadri L, Yoneyama R, Hoshino K, Takewa Y, Sakata S, Peluso R, Zsebo K, Gwathmey JK, Tardif JC, Tanguay JF, Hajjar RJ. Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol 51: 1112-1119, 2008.
24. Lafont A, Loirand G, Pacaud P, Vilde F, Lemarchand P, Escande D. Vasomotor dysfunction early after exposure of rabbit arteries to an adenoviral vector. Hum Gene Ther 10: 1033-1040, 1997.
25. 2+ handling capacity. Circ Res 89: 160-167, 2001.
26. LaNoue KF, Nicklas WJ, Williamson JR. Control of citric acid cycle activity in rat heart mitochondria. J Biol Chem 245: 102-111, 1970.
27. Lewandowski ED, O'Donnell JM, Scholz TD, Sorokina N, Buttrick PM. Recruitment of NADH Shuttling in pressure overloaded and hypertrophic rat hearts. Am J Physiol Cell Physiol 292: C1880-C1886, 2007.
28. Li L, DeSantiago J, Chu G, Kranias EG, Bers SM. Phosphorylation of phospholamban and troponin I in β-adrenergic-induced acceleration of cardiac relaxation. Am J Physiol Heart Circ Physiol 278: H769-H779, 2000.
29. Logeart D, Vinet L, Ragot T, Heimburger M, Louedec L, Michel JB, Escoubet B, Mercadier JJ. Percutaneous intracoronary delivery of SERCA gene increases myocardial function: a tissue Doppler imaging echocardiographic study. Am J Physiol Heart Circ Physiol 291: H1773-H1779, 2006.
30. 2+-ATPase. Circ Res 83: 889-897, 1998.
31. MacGowan GA. The myofilament force-calcium relationship as a target for positive inotropic therapy in congestive heart failure. Cardiovasc Drugs Ther 19: 203-210, 2005.
32. 13C NMR spectroscopy. J Biol Chem 263: 6965-6971, 1989.
33. 13 (SERCA)-pumps: link to heart beats and calcium waves. Cell Calcium 25: 277-290, 1999.
34. Miyamoto MI, del Monte F, Schmidt U, DiSalvo TS, Kang ZB, Matsui T, Guerrero JL, Gwathmey JK, Rosenzweig A, Hajjar RJ. Adenoviral gene transfer of SERCA2a improves left-ventrcular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci USA 97: 793-798, 2000.
35. O'Donnell JM, Alpert NM, White L, Lewandowski ED. Coupling of mitochondrial fatty acid uptake to oxidative flux in the intact heart. Biophys J 82: 11-18, 2002.
36. O'Donnell JM, Lewandowski ED. Efficient, cardiac-specific adenoviral gene transfer by isolated retrograde perfusion in vivo. Gene Ther 12: 958-965, 2005.
37. O'Donnell JM, Zampino M, Alpert NM, Fasano MJ, Geenen DL, Lewandowski ED. Accelerated triacylglycerol turnover kinetics in hearts of diabetic rats include evidence for compartmented lipid storage. Am J Physiol Endocrinol Metab 290: E448-E455, 2006.
38. O'Donnell JM, Lewandowski ED. Controlling specificity and efficiency of adenoviral gene transfer in heart by catheter-based coronary perfusion. In: Gene Therapy: Prospective Assessment in Its Societal Context, edited by Niewohner J and Tannert C. Amsterdam, Netherlands: Elsevier, 2006, p. 33-46.
39. O'Donnell JM, Sumbilla C, Hailun M, Farrance I, Cavagna M, Klein M, Inesi G. Tight control of exogenous SERCA expression is required to obtain acceleration of calcium transients with minimal cytotoxic effect in cardiac myocytes. Circ Res 88: 415-421, 2001.
40. O'Donnell JM, Doumen C, LaNoue KF, White LT, Yu X, Alpert NM, Lewandowski ED. Dehydrogenase regulation of metabolite oxidation and efflux from mitochondria in intact hearts. Am J Physiol Heart Circ Physiol 274: H467-H476, 1998.
41. cp rat heart. J Mol Cell Cardiol 30: 235-241, 1998.
42. O'Donnell JM, Fields A, Sorokina N, Lewandowski ED. The absence of endogenous lipid oxidation in early stage heart failure exposes limits in lipid storage and turnover. J Mol Cell Physiol 44: 315-322, 2008.
43. Perez NG, Hashimoto K, McCune S, Altschuld RA, Marban E. Origin of contractile dysfunction in heart failure: calcium cycling versus myofilaments. Circulation 99: 1077-1083, 1999.
44. Periasamy M, Kalyanasundaram A. SERCA pump isoforms: their role in calcium transport and disease. Muscle Nerve 35: 430-442, 2007.
45. cp homeostasis and cardiac contractility. J Mol Cell Cardiol 33: 1053-1063, 2001.
46. Ribeiro HB, Okoshi K, Cicogna AC, Bregagnollo EA, Rodrigues MA, Padovani CR, Aragon FF, Jamas E, Okoshi MP. Follow-up study of morphology and cardiac function in rats undergoing induction of supravalvular aortic stenosis. Arq Bras Cardiol 81: 569-575, 2003.
47. 2+ induced arrhythmogensis. J Cardiovasc Pharmacol Ther 10: 235-249, 2005.
48. Sack MN, Rader TA, Park S, Bastin J, McCune SA, Kelly DP. Fatty acid oxidation enzyme gene expression is down regulated in the failing heart. Circulation 94: 2837-2842, 1996.
49. 2+-ATPase, alter heart rate and rhythmicity in Drosophila. J Comp Physiol 176: 253-263, 2006.
50. Sorokina N, O'Donnell JM, McKinney RD, Pound KM, Woldegiorgis G, LaNoue KF, Ballal K, Taegtmeyer H, Buttrick PM, Lewandowski ED. Recruitment of compensatory pathways to sustain oxidative flux with reduced carnitine palmitoyltransferase I activity characterizes inefficiency in energy metabolism in hypertrophied hearts. Circulation 155: 2033-2041, 2007.
51. Stanley WC, Chandler MP. Energy metabolism in the normal and failing heart: potential for therapeutic interventions. Heart Fail Rev 7: 115-130, 2002.
52. Sumbilla C, Cavagna M, Zhong L, Ma H, Lewis D, Farrance I, Inesi G. Comparison of SERCA1 and SERCA2a expressed in COS-1 cells and cardiac myocytes. Am J Physiol Heart Circ Physiol 277: H2381-H2391, 1999.
53. TenHove M, Neubauer S. MR spectroscopy in heart failure-clinical and experimental findings. Heart Fail Rev 12: 48-57, 2007.
54. 2+ uptake but decreases myocyte shortening. Circulation 110: 3553-3559, 2004.
55. 2+ handling contributes to decreased contractile reserve in rat hearts. Am J Physiol Heart Circ Physiol 275: H2065-H2071, 1998.
56. Tian R, Ingwall JS. The molecular energetics of the failing heart from animal models-small animal models. Heart Fail Rev 4: 245-253, 1999.
57. Ungerer M, Bohm M, Elce JS, Erdmann E, Lohse MJ. Altered expression of β-adrenergic receptor kinase and β-adrenergic receptors in the failing human heart. Circulation 87: 454-463, 1993.
58. Van Bilsen M, Smeets PJH, Gilde AJ, van der Vusse GJ. Metabolic remodeling of the failing heart: the cardiac burn-out syndrome? Cardiovasc Res 61: 218-226, 2004.
59. 2+ affinity can lead to severe cardiac hypertrophy, stress intolerance and reduced life span. J Mol Cell Cardiol 41: 308-317, 2006.
60. Vatner DE, Ingwall JS. Effects of moderate pressure-overload cardiac hypertrophy on the distribution of creatine kinase isozymes. Proc Soc Exp Biol Med 175: 5-9, 1984.
61. 2+-ATPase in skeletal muscle. Biochem J 340: 667-669, 1999.
62. Weisser-Thomas J, Dieterich E, Janssen PML, Schmidt-Schweda S, Maier LS, Sumbilla C, Pieske B. Method-related effects of adenovirus-mediated LacZ and SERCA1 gene transfer on contractile behavior of cultured failing human cardiomyocytes. J Pharm Tox Meth 51: 91-103, 2005.
63. 2+-ATPase isoforms: diverse responses to acidosis. Biochem J 321: 545-550, 1997.
64. Wright MJ, Rosenthal E, Stewart L, Wightman LML, Miller AD, Latchman DS, Marber MS. β-Galactosidase staining following intracoronary infusion of cationic liposomes in the in vivo rabbit heart is produced by microinfarction rather than effective gene transfer: a cautionary tale. Gene Ther 5: 301-308, 1998.
65. 13C NMR spectra: metabolic flux, regulation, and compartmentation in hearts. Biophys J 69: 2090-2102, 1995.
66. 13C NMR spectra: theoretical analysis and practical considerations. Am J Physiol Cell Physiol 272: C2037-C2048, 1997.